{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:33:40Z","timestamp":1776404020039,"version":"3.51.2"},"reference-count":55,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Public Health Services Research","award":["R01 DK97830"],"award-info":[{"award-number":["R01 DK97830"]}]},{"name":"Public Health Services Research","award":["K23 DK107937"],"award-info":[{"award-number":["K23 DK107937"]}]},{"name":"Public Health Services Research","award":["UL1 TR001878"],"award-info":[{"award-number":["UL1 TR001878"]}]},{"name":"University of Pennsylvania Center for Human Phenomic Science","award":["P30 DK19525"],"award-info":[{"award-number":["P30 DK19525"]}]},{"name":"University of Pennsylvania Diabetes Research Center","award":["T32 DK007314"],"award-info":[{"award-number":["T32 DK007314"]}]},{"name":"University of Pennsylvania Training Grant in Diabetes, Endocrine and Metabolic Diseases"},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Human Metabolism Resource of the University of Pennsylvania Institute for Diabetes, Obesity & Metabolism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Investigator","doi-asserted-by":"publisher","award":["50512"],"award-info":[{"award-number":["50512"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Impaired incretin secretion may contribute to the defective insulin secretion and abnormal glucose tolerance (AGT) that associate with worse clinical outcomes in pancreatic insufficient cystic fibrosis (PI-CF). The study objective was to test the hypothesis that dipeptidyl peptidase-4 (DPP-4) inhibitor-induced increases in intact incretin hormone [glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)] concentrations augment insulin secretion and glucagon suppression and lower postprandial glycemia in PI-CF with AGT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>26 adults from Children\u2019s Hospital of Philadelphia and University of Pennsylvania CF Center with PI-CF and AGT [defined by oral glucose tolerance test glucose (mg\/dL): early glucose intolerance (1-h\u2005\u2265\u2005155 and 2-h\u2005&amp;lt;\u2005140), impaired glucose tolerance (2-h\u2005\u2265\u2005140 and &amp;lt;\u2005200 mg\/dL), or diabetes (2-h\u2005\u2265\u2005200)] were randomized to a 6-month double-blind trial of DPP-4 inhibitor sitagliptin 100 mg daily or matched placebo; 24 completed the trial (n = 12 sitagliptin; n = 12 placebo). Main outcome measures were mixed-meal tolerance test (MMTT) responses for intact GLP-1 and GIP, insulin secretory rates (ISRs), glucagon suppression, and glycemia and glucose-potentiated arginine (GPA) test-derived measures of \u03b2- and \u03b1-cell function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Following 6-months of sitagliptin vs placebo, MMTT intact GLP-1 and GIP responses increased (P &amp;lt; 0.001), ISR dynamics improved (P &amp;lt; 0.05), and glucagon suppression was modestly enhanced (P &amp;lt; 0.05) while GPA test responses for glucagon were lower. No improvements in glucose tolerance or \u03b2-cell sensitivity to glucose, including for second-phase insulin response, were found.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In glucose intolerant PI-CF, sitagliptin intervention augmented meal-related incretin responses with improved early insulin secretion and glucagon suppression without affecting postprandial glycemia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab365","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T16:58:42Z","timestamp":1621702722000},"page":"2617-2634","source":"Crossref","is-referenced-by-count":37,"title":["Effect of Sitagliptin on Islet Function in Pancreatic Insufficient Cystic Fibrosis With Abnormal Glucose Tolerance"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1724-9868","authenticated-orcid":false,"given":"Andrea","family":"Kelly","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Diabetes, Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphias, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darko","family":"Stefanovski","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Pennsylvania School of Veterinary Medicine, Kennett Square, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy J","family":"Peleckis","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah C","family":"Nyirjesy","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack N","family":"Eiel","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniket","family":"Sidhaye","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Localio","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gallop","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA"},{"name":"Department of Mathematics, West Chester University of Pennsylvania, West Chester, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diva D","family":"De Leon","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Hadjiliadis","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald C","family":"Rubenstein","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Philadelphias, PA, USA"},{"name":"Division of Allergy and Pulmonary Medicine, Department of Pediatrics, Washington University in St. Louis School of Medicine, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9253-838X","authenticated-orcid":false,"given":"Michael R","family":"Rickels","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"issue":"9","key":"2021120919234224400_CIT0001","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care."},{"issue":"12","key":"2021120919234224400_CIT0002","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.2337\/dc10-1279","article-title":"Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care."},{"issue":"5","key":"2021120919234224400_CIT0003","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jpeds.2004.12.039","article-title":"Epidemiology of cystic fibrosis-related diabetes","volume":"146","author":"Marshall","year":"2005","journal-title":"J Pediatr."},{"issue":"1","key":"2021120919234224400_CIT0004","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2337\/db16-0394","article-title":"Reduced \u03b2-cell secretory capacity in pancreatic-insufficient, but not pancreatic-sufficient, cystic fibrosis despite normal glucose tolerance","volume":"66","author":"Sheikh","year":"2017","journal-title":"Diabetes."},{"issue":"7","key":"2021120919234224400_CIT0005","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/pedi.12700","article-title":"\u03b2-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose \u2265155\u2009mg\/dL","volume":"19","author":"Nyirjesy","year":"2018","journal-title":"Pediatr Diabetes."},{"issue":"10","key":"2021120919234224400_CIT0006","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc09-0585","article-title":"Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care."},{"issue":"10","key":"2021120919234224400_CIT0007","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1007\/s00125-020-05210-8","article-title":"A tale of two pancreases: exocrine pathology and endocrine dysfunction","volume":"63","author":"Rickels","year":"2020","journal-title":"Diabetologia."},{"issue":"4","key":"2021120919234224400_CIT0008","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2337\/dc17-1387","article-title":"Islet Interleukin-1\u03b2 immunoreactivity is an early feature of cystic fibrosis that may contribute to \u03b2-cell failure","volume":"41","author":"Hull","year":"2018","journal-title":"Diabetes Care."},{"issue":"3","key":"2021120919234224400_CIT0009","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.201806-1018OC","article-title":"Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med."},{"issue":"5","key":"2021120919234224400_CIT0010","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz102","article-title":"Genetic modifiers of cystic fibrosis-related diabetes have extensive overlap with type 2 diabetes and related traits","volume":"105","author":"Aksit","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021120919234224400_CIT0011","doi-asserted-by":"crossref","first-page":"E851","DOI":"10.1210\/jc.2010-2460","article-title":"Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis\u2013effects of pancreatic enzyme supplementation","volume":"96","author":"Kuo","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2021120919234224400_CIT0012","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1210\/jc.2013-4417","article-title":"Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial","volume":"99","author":"Perano","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021120919234224400_CIT0013","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc07-0228","article-title":"Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action","volume":"30","author":"Drucker","year":"2007","journal-title":"Diabetes Care."},{"issue":"12","key":"2021120919234224400_CIT0014","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care."},{"issue":"12","key":"2021120919234224400_CIT0015","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diabetes Care."},{"issue":"1","key":"2021120919234224400_CIT0016","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinthera.2006.01.015","article-title":"Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers","volume":"28","author":"Bergman","year":"2006","journal-title":"Clin Ther."},{"issue":"11","key":"2021120919234224400_CIT0017","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1210\/jc.2006-1009","article-title":"Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes","volume":"91","author":"Herman","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021120919234224400_CIT0018","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1210\/jc.2012-1205","article-title":"Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes","volume":"97","author":"Muscelli","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2021120919234224400_CIT0019","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jcf.2019.08.011","article-title":"Cystic fibrosis related diabetes: nutrition and growth considerations","volume":"18","author":"Kaminski","year":"2019","journal-title":"J Cyst Fibros."},{"issue":"2","key":"2021120919234224400_CIT0020","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2008.05.005","article-title":"Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report","volume":"153","author":"Farrell","year":"2008","journal-title":"J Pediatr."},{"issue":"5","key":"2021120919234224400_CIT0021","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1210\/jc.2012-4127","article-title":"Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society","volume":"98","author":"Seaquist","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021120919234224400_CIT0022","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2337\/db07-1124","article-title":"Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance","volume":"57","author":"Vollmer","year":"2008","journal-title":"Diabetes."},{"issue":"2","key":"2021120919234224400_CIT0023","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S2213-8587(17)30400-X","article-title":"Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial","volume":"6","author":"Ballmann","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"2021120919234224400_CIT0024","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1172\/JCI115779","article-title":"Effects of hemipancreatectomy on pancreatic alpha and beta cell function in healthy human donors","volume":"89","author":"Seaquist","year":"1992","journal-title":"J Clin Invest."},{"issue":"3","key":"2021120919234224400_CIT0025","doi-asserted-by":"crossref","first-page":"E557","DOI":"10.1152\/ajpendo.00325.2002","article-title":"Improved beta-cell function after standardized weight reduction in severely obese subjects","volume":"284","author":"Guldstrand","year":"2003","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"9","key":"2021120919234224400_CIT0026","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2337\/dc14-0398","article-title":"Effect of exenatide, sitagliptin, or glimepiride on \u03b2-cell secretory capacity in early type 2 diabetes","volume":"37","author":"Gudipaty","year":"2014","journal-title":"Diabetes Care."},{"issue":"5 Pt 1","key":"2021120919234224400_CIT0027","first-page":"E405","article-title":"Adaptation of B and A cell function during prolonged glucose infusion in human subjects","volume":"246","author":"Ward","year":"1984","journal-title":"Am J Physiol."},{"issue":"7","key":"2021120919234224400_CIT0028","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s001250050986","article-title":"Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine","volume":"41","author":"Larsson","year":"1998","journal-title":"Diabetologia."},{"key":"2021120919234224400_CIT0029","volume-title":"RRID:AB_2801577"},{"key":"2021120919234224400_CIT0030","volume-title":"RRID:AB_2891151"},{"key":"2021120919234224400_CIT0031","volume-title":"RRID:AB_2757819"},{"key":"2021120919234224400_CIT0032","volume-title":"RRID:AB_2891152"},{"issue":"4","key":"2021120919234224400_CIT0033","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/dom.13192","article-title":"Effect of single-dose DPP-4 inhibitor sitagliptin on \u03b2-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-na\u00efve, well-controlled type 2 diabetes subjects","volume":"20","author":"Alsalim","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"7","key":"2021120919234224400_CIT0034","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/dom.13276","article-title":"Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients","volume":"20","author":"Alsalim","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"2021120919234224400_CIT0035","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1152\/ajpendo.2001.280.1.E2","article-title":"Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models","volume":"280","author":"Toffolo","year":"2001","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"12","key":"2021120919234224400_CIT0036","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1007\/s00125-011-2322-2","article-title":"Proinsulin-to-C-peptide ratio versus proinsulin-to-insulin ratio in the prediction of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS)","volume":"54","author":"Loopstra-Masters","year":"2011","journal-title":"Diabetologia."},{"issue":"6","key":"2021120919234224400_CIT0037","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1172\/JCI108047","article-title":"Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood","volume":"55","author":"Horwitz","year":"1975","journal-title":"J Clin Invest."},{"issue":"6","key":"2021120919234224400_CIT0038","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J."},{"issue":"1","key":"2021120919234224400_CIT0039","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1210\/jc.2008-1806","article-title":"Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients","volume":"94","author":"Rickels","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"2021120919234224400_CIT0040","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/bimj.4710390803","article-title":"Sample size and power calculation for periodontal and other studies with clustered samples using the method of generalized estimating equations","volume":"39","author":"Shih","year":"1997","journal-title":"Biom J."},{"key":"2021120919234224400_CIT0041","volume-title":"Linear Mixed Models for Longitudinal Data.","author":"Verbeke","year":"2000"},{"issue":"20","key":"2021120919234224400_CIT0042","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJM200005183422001","article-title":"A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression","volume":"342","author":"Keller","year":"2000","journal-title":"N Engl J Med."},{"key":"2021120919234224400_CIT0043","doi-asserted-by":"crossref","DOI":"10.1201\/b16446","volume-title":"Quasi-Least Squares Regression.","author":"Shults","year":"2014"},{"issue":"1","key":"2021120919234224400_CIT0044","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3102\/10769986024001070","article-title":"Sample size estimation for longitudinal designs with attrition: comparing time-related contrasts between two groups","volume":"24","author":"Hedeker","year":"1999","journal-title":"J Educ Behav Stat."},{"issue":"8","key":"2021120919234224400_CIT0045","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1463-1326.2010.01208.x","article-title":"Reactive hypoglycaemia following GLP-1 infusion in pancreas transplant recipients","volume":"12","author":"Rickels","year":"2010","journal-title":"Diabetes Obes Metab."},{"key":"2021120919234224400_CIT0046","volume-title":"Sitagliptin package insert 2019"},{"issue":"6","key":"2021120919234224400_CIT0047","first-page":"1778","article-title":"Glucose modulation of insulin and glucagon-secretion is altered in impaired glucose-tolerance","volume":"80","author":"Larsson","year":"1995","journal-title":"J Clin Endocrinol Metabol."},{"issue":"5","key":"2021120919234224400_CIT0048","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes."},{"issue":"1","key":"2021120919234224400_CIT0049","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia."},{"issue":"6","key":"2021120919234224400_CIT0050","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00125-003-1103-y","article-title":"Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia","volume":"46","author":"Meier","year":"2003","journal-title":"Diabetologia."},{"issue":"2","key":"2021120919234224400_CIT0051","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1677\/joe.0.1720355","article-title":"Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs","volume":"172","author":"Deacon","year":"2002","journal-title":"J Endocrinol."},{"issue":"3","key":"2021120919234224400_CIT0052","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/dom.13544","article-title":"Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: a randomized crossover trial","volume":"21","author":"Geyer","year":"2019","journal-title":"Diabetes Obes Metab."},{"key":"2021120919234224400_CIT0053","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jcf.2019.08.015","article-title":"Energy balance and obesity in individuals with cystic fibrosis","volume":"18","author":"Litvin","year":"2019","journal-title":"J Cyst Fibros."},{"issue":"1","key":"2021120919234224400_CIT0054","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide-1 [7-36 Amide] but not of synthetic human gastric-inhibitory polypeptide in patients with type-2 diabetes-mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Investig."},{"issue":"8","key":"2021120919234224400_CIT0055","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","article-title":"Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients","volume":"45","author":"Vilsb\u00f8ll","year":"2002","journal-title":"Diabetologia."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab365\/38961304\/dgab365.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/9\/2617\/41689119\/dgab365.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/9\/2617\/41689119\/dgab365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T19:24:43Z","timestamp":1639077883000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/9\/2617\/6281094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":55,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5,22]]},"published-print":{"date-parts":[[2021,8,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab365","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,5,22]]}}}